What is Valinor?
Valinor operates at the intersection of biotechnology and artificial intelligence, specializing in the development of patient-derived datasets and predictive models designed to optimize drug discovery. By integrating machine learning with high-fidelity clinical data, the firm enables developers to forecast patient responses with unprecedented accuracy. This approach effectively de-risks the development process, reducing the reliance on traditional trial-and-error methodologies that have historically plagued the industry. Valinor's platform serves as a force multiplier for therapeutic R&D, offering a scalable solution to enhance success rates across diverse drug modalities and therapeutic areas.
How much funding has Valinor raised?
Valinor has raised a total of $13M across 1 funding round:
Seed
$13M
Seed (2025): $13M with participation from Harpoon Ventures, Pelion Venture Partners, Amino Collective, and Charles River Ventures
Key Investors in Valinor
Harpoon Ventures
Harpoon Ventures is an investment firm focused on backing bold leaders who are developing mission-critical technologies across various sectors, including AI, deep tech, software infrastructure, and cybersecurity.
Pelion Venture Partners
Pelion Venture Partners manages a portfolio of funds, focusing on investment solutions for its clients and supporting early-stage ventures through a managed fund approach.
Amino Collective
Amino Collective focuses on investing in health and bio sectors, supporting early-stage ventures with a European focus that aim to scale globally.
What's next for Valinor?
With this major enterprise-level funding, Valinor is poised to expand its technical infrastructure and deepen its integration within the global drug development ecosystem. The strategic focus will likely center on broadening the scope of its predictive models to encompass a wider array of complex diseases, thereby increasing the utility of its platform for large-scale pharmaceutical partners. Furthermore, the company is expected to leverage its recent capital to attract top-tier talent in data science and clinical research, ensuring that its technological edge remains sharp in an increasingly competitive biotech landscape. As Valinor continues to refine its proprietary datasets, the firm is set to play an instrumental role in shortening the time-to-market for life-saving therapies.
See full Valinor company page
